Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Renovaro Inc (RENB)

Renovaro Inc (RENB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 177,763
  • Shares Outstanding, K 158,717
  • Annual Sales, $ 0 K
  • Annual Income, $ -80,650 K
  • EBIT $ -24 M
  • EBITDA $ 31 M
  • 60-Month Beta 0.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.70

Options Overview Details

View History
  • Implied Volatility 156.25% ( -29.50%)
  • Historical Volatility 203.42%
  • IV Percentile 27%
  • IV Rank 12.68%
  • IV High 956.12% on 11/07/24
  • IV Low 40.11% on 09/13/24
  • Put/Call Vol Ratio 1.83
  • Today's Volume 690
  • Volume Avg (30-Day) 324
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 2,405
  • Open Int (30-Day) 1,954

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5000 +106.00%
on 11/26/24
2.1000 -50.95%
on 12/09/24
+0.5110 (+98.46%)
since 11/22/24
3-Month
0.3950 +160.76%
on 10/09/24
2.1000 -50.95%
on 12/09/24
+0.5475 (+113.47%)
since 09/24/24
52-Week
0.3950 +160.76%
on 10/09/24
5.2500 -80.38%
on 01/25/24
-2.2200 (-68.31%)
since 12/22/23

Most Recent Stories

More News
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

RENB : 1.0300 (-8.04%)
Renovaro Regains Compliance with NASDAQ Listing Requirement

RENB : 1.0300 (-8.04%)
Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

RENB : 1.0300 (-8.04%)
Renovaro: Fiscal Q1 Earnings Snapshot

Renovaro: Fiscal Q1 Earnings Snapshot

RENB : 1.0300 (-8.04%)
Renovaro Issues Shareholder Letter and Provides Corporate Update

RENB : 1.0300 (-8.04%)
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

RENB : 1.0300 (-8.04%)
Renovaro Announces Strategic Restructuring and Leadership Transition

RENB : 1.0300 (-8.04%)
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

ONCY : 0.9700 (+7.09%)
ONC.TO : 1.41 (+9.30%)
RENB : 1.0300 (-8.04%)
CYTO : 0.3000 (-25.94%)
PFE : 26.74 (+0.11%)
ABBV : 180.00 (+0.90%)
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

ONCY : 0.9700 (+7.09%)
ONC.TO : 1.41 (+9.30%)
RENB : 1.0300 (-8.04%)
CYTO : 0.3000 (-25.94%)
PFE : 26.74 (+0.11%)
ABBV : 180.00 (+0.90%)
Renovaro BioSciences (NASDAQ: RENB) Announces Results of Special Meeting

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced the results of its special meeting of shareholders (“special meeting”) held...

RENB : 1.0300 (-8.04%)

Business Summary

Renovaro Inc. includes RenovaroCube and Renovaro Biosciences. Renovaro Biosciences is an advanced cell-gene-immunotherapy company. Its lead candidate product is a therapeutic vaccine targeting cancers which are difficult to treat including pancreatic and potentially HNC, triple-negative breast cancer,...

See More

Key Turning Points

3rd Resistance Point 1.6600
2nd Resistance Point 1.3900
1st Resistance Point 1.2100
Last Price 1.0300
1st Support Level 0.7600
2nd Support Level 0.4900
3rd Support Level 0.3100

See More

52-Week High 5.2500
Fibonacci 61.8% 3.3954
Fibonacci 50% 2.8225
Fibonacci 38.2% 2.2496
Last Price 1.0300
52-Week Low 0.3950

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar